Medical Licensing (MD/DO) · Independent exam preparation
ABPath Cytopathology Subspecialty: Diagnostic Reasoning and Practice Guide Study Guide
Practise cytomorphologic distinctions, specimen triage, ancillary-test interpretation and laboratory decisions for the ABPath Cytopathology subspecialty exam.
By CertMedbry · Updated 15 October 2026
Distinguish malignant cells from their mimics, preserve specimens for decisive ancillary studies, and connect cytologic findings with appropriate reporting and laboratory action. This selective guide develops 60 diagnostic and operational concepts for physician-level ABPath Cytopathology subspecialty preparation. Use the January 2026 official content specifications as the reference for the full examination scope; ABPath also explains that its specifications are not exhaustive. Pair these text exercises with supervised slide review and virtual-microscopy practice.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide address?
The ABPath Cytopathology subspecialty certification examination for physicians. The January 2026 specifications emphasize fellow-level knowledge together with applicable core and advanced-resident knowledge. This is a subspecialty board examination, rather than a general medical licensing examination.
ABPath Cytopathology Exam Description · ABPath Cytopathology Content Specifications, January 2026
How many questions are published, and are scored and pretest counts identified?
ABPath publishes 220 combined Written/Practical questions and 70 Virtual Microscopy questions, totaling 290. The 2026 schedule divides these into Written/Practical sections of 74, 73 and 73 items and Virtual Microscopy sections of 24, 23 and 23 items. Separate scored and pretest counts are not identified in these publications.
ABPath Cytopathology Exam Description · ABPath 2026 Cytopathology (CY) Exam Schedule
What examination duration is supported?
The examination-description page lists 4 hours 20 minutes for Written/Practical and 3 hours 32 minutes for Virtual Microscopy. The blueprint marked Updated for 2026 prints 4 hours 4 minutes and 3 hours 48 minutes, respectively; the 2026 schedule's section times total those same durations. Both allocations total 7 hours 52 minutes. Because the examination-description page differs from the blueprint and schedule, use administration-specific instructions for section timing and breaks.
ABPath Cytopathology Exam Description · ABPath Cytopathology Examination Blueprint, updated for 2026 · ABPath 2026 Cytopathology (CY) Exam Schedule
How is the examination delivered, and what item styles are described?
ABPath describes a one-day computer-based examination using multiple-choice, single-best-answer questions. There are no glass slides; slide assessment uses virtual microscopy. Practical questions integrate interpretation, problem solving, clinical and radiologic correlation, histology and management. Virtual microscopy also assesses locator skills. Cervical/anal slides are typically dotted, whereas FNA and non-gynecologic slides usually are not. ABPath does not describe an adaptive delivery model on its examination-description page.
Which outline and blueprint versions apply?
The current specifications index identifies Cytopathology as Final Version and links the specifications dated 1/2026. The separate blueprint is marked Updated for 2026. Neither statement establishes a separate implementation date. Specifications enumerate possible subjects; the blueprint gives approximate section-specific percentages. ABPath's listed references include thyroid Bethesda third edition, Milan second edition, Paris second edition and cervical Bethesda third edition, supplemented by applicable clinical guidance.
ABPath Content Specifications for Examinations · ABPath Cytopathology Content Specifications, January 2026 · ABPath Cytopathology Examination Blueprint, updated for 2026 · ABPath Candidate Resource Guide, 2026 · ABPath Guidelines and Key Manuscripts
What approximate category weights does the 2026 blueprint publish?
Each pair below is Written/Practical followed by Virtual Microscopy: shared genital group 13%/14%; effusions and pelvic washings 8%/13%; synovial fluid, CSF and CNS/eye 4%/3%; urinary tract 5%/7%; respiratory specimens and lung FNA 8%/13%; esophagus, stomach and bowel/appendix 1%/0%; liver 5%/6%; biliary/gallbladder and pancreas 6%/9%; salivary FNA 5%/7%; thyroid/parathyroid FNA 8%/9%; lymph-node FNA 5%/4%; other head/neck and intraoral sites 5%/3%; breast/nipple 1%/1%; mediastinum/retroperitoneum 4%/3%; kidney/adrenal 3%/4%; superficial lumps, skin, soft tissue and bone 4%/4%; laboratory administration, management, techniques and procedures 15%/0%. Each column totals 100%. A combined category's weight applies once to the group.
ABPath Cytopathology Examination Blueprint, updated for 2026
How do the three guide domains relate to the weighted blueprint?
The three labels follow ABPath's examination-description groupings. The blueprint's shared genital group includes cervical/vaginal, lower anogenital and upper female genital specimens together with male GU/testis/prostate. The female and lower-anogenital subjects map to Gynecologic/Anal Cytopathology; male GU/testis/prostate maps to Non-Gynecologic and Fine Needle Aspiration Cytopathology. Their shares cannot be separated numerically. Other diagnostic groups total 72% Written/Practical and 86% Virtual Microscopy. Laboratory Management/Administration maps to 15%/0%. This guide uses 8, 43 and 9 concepts and 3, 14 and 3 questions and cards, respectively, as a selective approximation of Written/Practical emphasis.
ABPath Cytopathology Exam Description · ABPath Cytopathology Examination Blueprint, updated for 2026
How should these questions and flashcards be used?
The 20 four-option questions are independent learning drills. They practise diagnostic reasoning and selected laboratory decisions; they do not reproduce virtual-slide navigation or provide pass prediction. The 20 flashcards support active recall. Use the full official specifications to identify additional study needs, especially entities and procedures outside these selective examples. United States CLIA requirements are explicitly identified and should not be generalized to other jurisdictions.
ABPath Cytopathology Content Specifications, January 2026 · 42 CFR 493.1274: Cytology
This guide addresses the American Board of Pathology Cytopathology subspecialty certification examination. The specifications' phrase 'Fundamental Knowledge and Skills' does not identify a separate credential. These independently authored learning materials are not endorsed by ABPath and do not reproduce official examination questions.
Outline used: Current ABPath Cytopathology Content Specifications, designated Final Version and dated 1/2026, together with the examination blueprint marked Updated for 2026. Neither document states a separate effective date. Examination identity, the final-specifications index, the January 2026 specifications and the issuer's blueprint link were independently reopened on 2026-10-09. Complete blueprint percentages come from the supplied trusted frozen primary-issuer extract retrieved at 2026-10-09T04:58:57.193220+00:00, not a newly readable live table. Both percentage columns independently total 100%. The workbook label maps directly to ABPath's Cytopathology subspecialty certification examination; the assigned slug is preserved. The three retained domains are examination-description groupings. Their crosswalk explicitly preserves the shared genital category, whose 13% Written/Practical and 14% Virtual Microscopy weights include male GU specimens and cannot be attributed entirely to the narrower Gynecologic/Anal domain.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Gynecologic/Anal CytopathologyNot separately stated: included within the shared genital group, approximately 13% Written/Practical and 14% Virtual Microscopy; that group also includes male GU/testis/prostate.
1.What makes a perinuclear halo convincing for LSIL?
Koilocytosis combines a sharply defined perinuclear cavity with genuine nuclear atypia, including enlargement, hyperchromasia and irregular nuclear contours. Binucleation can reinforce the impression but does not independently establish LSIL. The decisive distinction is between an HPV-associated cytopathic pattern and nonspecific cytoplasmic clearing. Glycogen, inflammation and preparation effects can produce halos without dysplastic nuclei. Assess the nucleus and the surrounding cytoplasmic rim together before assigning a squamous intraepithelial lesion.
Apply it
A cervical preparation contains mature squamous cells with broad pale perinuclear zones. Most nuclei remain small and smooth. Search for convincing nuclear atypia before classifying the clearing as koilocytosis or reporting LSIL.
Common pitfall: A halo alone is a tempting visual shortcut. Perinuclear clearing without the accompanying nuclear abnormalities does not establish an HPV-associated squamous lesion.
2.Which nuclear features favor HSIL over an atrophic pattern?
HSIL typically contains immature squamous cells with disproportionately large nuclei, scant cytoplasm, irregular nuclear membranes and abnormal chromatin. Atrophy can also produce crowded parabasal cells with high nuclear-to-cytoplasmic ratios, making cell size alone unreliable. Seek a coherent population showing true nuclear irregularity and dysplastic chromatin rather than uniform, smooth nuclei in an atrophic background. Degeneration and inflammation must be assessed separately because they can exaggerate darkness without reproducing the full high-grade pattern.
Apply it
A postmenopausal patient's smear shows many small parabasal cells. A separate population has sharply irregular nuclear contours and coarse chromatin. Evaluate that population independently instead of explaining every abnormal cell through atrophy.
Common pitfall: High nuclear-to-cytoplasmic ratio is shared by benign immature cells. Calling HSIL from that feature alone ignores the discriminating nuclear membrane and chromatin findings.
IARC Cervical Cytology Atlas: HSIL · ABPath Cytopathology Content Specifications, January 2026
3.When should unsatisfactory cervical cytology be repeated?
An unsatisfactory result means that the available cellular material cannot support reliable cytologic interpretation. For unsatisfactory cytology with no, unknown or negative HPV testing, updated ASCCP guidance recommends repeating age-based screening as soon as convenient and no later than four months. A negative HPV result accompanying an unsatisfactory cytology specimen should not be treated as a valid reassuring screening result. Repeat cytology and HPV testing as appropriate; a second unsatisfactory cytology result warrants colposcopy.
Apply it
A cotest is reported as unsatisfactory cytology with negative HPV. The clinician proposes routine long-interval follow-up. Recommend repeat age-based screening within four months because the paired result does not provide usual negative-cotest reassurance.
Common pitfall: Waiting two months before recollection is no longer required. Equally, accepting the negative HPV result as routine reassurance overlooks the unsatisfactory specimen context.
4.How does p16 adjudicate an equivocal anogenital biopsy?
LAST uses p16 immunohistochemistry to help resolve selected histologic differentials, particularly a morphologic interpretation of CIN2 or uncertainty between a high-grade lesion and a benign mimic. Strong, diffuse block-type staining supports transforming HPV-associated disease when the morphology fits. Interpretation depends on the distribution and intensity of staining, not merely any positive cell. This is a biopsy adjudication principle; it does not replace cervical cytologic terminology or justify upgrading unequivocal low-grade morphology solely because p16 is positive.
Apply it
An anogenital biopsy has atypia that could represent immature metaplasia or a high-grade lesion. Assess appropriately controlled p16 staining with the architecture and nuclear findings to resolve that specific morphologic differential.
Common pitfall: Treating every positive p16 stain as HSIL confuses focal expression with block positivity and bypasses the requirement for an appropriate morphologic indication.
5.Which findings separate glandular atypia from reactive endocervical change?
Glandular assessment requires attention to architecture as well as individual nuclei. Reactive endocervical groups often retain orderly sheets, polarity and relatively uniform nuclei despite enlargement or nucleoli. Adenocarcinoma in situ may show crowded elongated nuclei, pseudostratification, feathered group edges, mitoses and apoptosis. No single feature is sufficient in isolation. Distinguish the cell population from squamous HSIL and consider endometrial or other origins when the architecture, background and clinical setting do not fit an endocervical process.
Apply it
A cervical sample shows crowded glandular strips with elongated hyperchromatic nuclei, feathered edges and apoptotic debris. Compare these groups with orderly reactive endocervical sheets before choosing a glandular abnormality category and recommending appropriate evaluation.
Common pitfall: Prominent nucleoli can occur in repair, while severe glandular disease may lack striking nucleoli. Nuclear size alone cannot reliably separate these processes.
6.Why do HPV vaccination and HPV testing answer different questions?
HPV vaccination is primary prevention: it helps prevent new infections with vaccine-targeted HPV types and their associated disease. It does not treat an established HPV infection or remove an existing lesion. HPV testing is a screening or risk-assessment tool that detects infection-related material and must be interpreted with the specimen, cytology and clinical history. Vaccination history therefore does not convert an abnormal screening result into a benign finding or eliminate the need for indicated screening and follow-up.
Apply it
A vaccinated patient has an abnormal cervical screening result and asks whether vaccination makes follow-up unnecessary. Explain that prevention of future infection and assessment of a current abnormal result require different decisions.
Common pitfall: Calling vaccination therapeutic can falsely reassure someone with an established lesion. Conversely, a positive HPV test does not mean that invasive cancer is present.
CDC Clinical Overview of HPV · ABPath Cytopathology Exam Description
7.How should anal squamous abnormalities be interpreted across specimen types?
Anal cytology assesses exfoliated squamous cells for abnormalities using nuclear and cytoplasmic features, including the distinction between low-grade HPV changes and high-grade immature dysplastic cells. Cytology provides a cellular interpretation, while biopsy permits evaluation of epithelial maturation and lesion architecture. LAST terminology concerns histologic classification of HPV-associated lower-anogenital lesions. Preserve these specimen-specific distinctions when correlating results: an abnormal cytology result and a biopsy diagnosis are related observations rather than interchangeable measurements of the same sampled tissue.
Apply it
An anal cytology specimen contains high-grade squamous cells, while a subsequent small biopsy shows only low-grade change. Review specimen sites and sampling adequacy before assuming that either interpretation must automatically be wrong.
Common pitfall: Applying biopsy p16 rules directly to an exfoliative cytology category confuses different diagnostic frameworks and can obscure a clinically meaningful sampling discrepancy.
ABPath Cytopathology Content Specifications, January 2026 · CAP-ASCCP LAST Recommendations
8.Why can an ovarian cyst aspirate underestimate a lesion?
An ovarian cyst aspirate samples luminal contents and whatever lining cells are shed or reached by the needle. A specimen dominated by macrophages, blood or debris may not represent the diagnostically important epithelial component. Cytologic blandness in such material therefore cannot establish that the entire lesion is benign. Correlate cellular findings with the sampled target and imaging, particularly any solid component or mural abnormality. The reporting decision should distinguish a genuinely informative benign pattern from limited representation.
Apply it
An ovarian cyst aspirate contains old blood and macrophages but no convincing epithelial component. Imaging shows a mural nodule. Describe the sampling limitation rather than allowing the bland fluid contents to resolve the nodule's significance.
Common pitfall: Aspirated fluid can appear reassuring because it lacks atypical cells. Absence of representative lesional epithelium limits what that negative observation can establish.
Non-Gynecologic and Fine Needle Aspiration CytopathologyNon-genital/nonlaboratory groups total approximately 72% Written/Practical and 86% Virtual Microscopy; male GU/testis/prostate additionally shares the unsplit genital group of 13%/14%, so the complete editorial domain has no separately stated percentage.
9.How does claudin-4 help distinguish carcinoma from mesothelial cells?
Claudin-4 is an epithelial tight-junction protein useful for identifying carcinoma in an effusion differential. Convincing staining in the atypical population supports epithelial carcinoma rather than mesothelial lineage. Its role differs from markers used to establish mesothelial differentiation or malignancy within a mesothelial population. Interpret the stain on the actual atypical cells, with adequate controls and a complementary panel. A lineage marker answers what the cells are; it does not by itself identify their primary anatomical site.
Apply it
A pleural-fluid cell block contains atypical cohesive groups among reactive mesothelial cells. Strong claudin-4 staining localizes to the atypical groups. Favor carcinoma and use clinical information plus selected markers to investigate the likely primary.
Common pitfall: Staining benign epithelial contaminants or interpreting background staining can misassign lineage. Confirm that the positive cells correspond to the morphologically concerning population.
10.What does BAP1 loss establish in a mesothelial population?
Loss of nuclear BAP1 expression in a population established as mesothelial supports a malignant mesothelial proliferation. The interpretation requires retained nuclear staining in internal control cells, demonstrating that apparent loss is not a technical failure. Retained BAP1 does not exclude mesothelioma because some malignant mesothelial tumors preserve expression. Establish lineage first, then assess the evidence for malignancy. Neither an uninterpretable stain nor BAP1 retention should override suspicious morphology and the broader clinical investigation.
Apply it
A pleural specimen contains atypical mesothelial cells with absent nuclear BAP1 staining, while lymphocytes stain normally. Integrate this controlled loss with mesothelial lineage and imaging as evidence supporting malignancy in the mesothelial population.
Common pitfall: Calling retained BAP1 proof of a reactive effusion reverses the test's logic. A marker can support malignancy through loss without excluding it through retention.
11.When should an effusion be triaged for a hematolymphoid workup?
A discohesive atypical lymphoid population in an effusion raises a different diagnostic problem from cohesive epithelial malignancy. Preserve material for morphology, cell-block immunophenotyping and, when appropriate, flow cytometry rather than consuming the specimen on a carcinoma-only panel. Cell viability and population representation affect flow results, so negative flow does not resolve every suspicious effusion. Integrating morphology and complementary studies helps distinguish reactive lymphocytosis, lymphoma and other hematopoietic processes while maintaining enough material for necessary classification.
Apply it
A pericardial effusion contains numerous large discohesive atypical cells and few mesothelial groups. Reserve a fresh aliquot for hematolymphoid studies while preparing a cell block, instead of assuming every malignant effusion represents metastatic adenocarcinoma.
Common pitfall: A negative flow result can reflect poor viability or an unsuitable target population. It should not erase convincing morphologic concern or prevent complementary evaluation.
CAP-ASCP: Laboratory Workup of Lymphoma in Adults · ABPath Cytopathology Content Specifications, January 2026
12.How is pleural-fluid adequacy linked to the intended ancillary test?
Adequacy is task-specific. A pleural-fluid specimen may demonstrate malignancy yet contain too few viable tumor cells for a particular molecular assay or predictive immunostain. Evaluate tumor quantity, tumor proportion, preservation and preparation type against the validated requirements of the intended test. Cell blocks and other validated cytology preparations can support ancillary studies, but fluid volume alone does not guarantee success. Communicate whether the limitation concerns diagnosis, ancillary testing or both so that further sampling addresses the actual unmet need.
Apply it
A large pleural-fluid collection yields a cell block with only scattered carcinoma cells. Before ordering several biomarkers, estimate available tumor and discuss whether a validated alternative preparation or another specimen would better support testing.
Common pitfall: A large submitted volume is not equivalent to abundant tumor. Likewise, a diagnosis of malignancy does not automatically establish adequacy for every predictive assay.
13.Which benign processes can mimic malignancy in pelvic washings?
Pelvic washings can contain reactive mesothelial groups, endometriosis, endosalpingiosis and collagenous aggregates. These differ from a spontaneous effusion because washing mechanically dislodges cells and tissue fragments. Ciliated, orderly Müllerian epithelium may reflect endosalpingiosis rather than metastatic carcinoma, while endometriosis may contribute endometrial-type elements and blood-related changes. Evaluate architecture, nuclear atypia, background and operative findings together. A cohesive epithelial group is an observation requiring classification, not automatic evidence of a malignant implant.
Apply it
A staging washing contains orderly ciliated epithelial groups without marked nuclear atypia. Review the surgical findings and consider benign tubal-type inclusions before interpreting the groups as dissemination of an ovarian epithelial malignancy.
Common pitfall: Equating every nonmesothelial epithelial group with metastatic cancer ignores benign Müllerian sources and the distinctive sampling effects of an intraoperative washing specimen.
14.Why does extracellular mucin in peritoneal material require careful sampling?
Abundant extracellular mucin in peritoneal material raises the possibility of a mucin-producing neoplastic process, including pseudomyxoma peritonei. The diagnostic epithelial component can be sparse or unevenly distributed, so acellular mucin and mucin containing atypical epithelium have different evidentiary value. Examine additional material and correlate with operative, imaging and histologic findings. Cytology can characterize sampled cells, but mucin alone does not reliably identify the primary organ or establish the full biological grade of the underlying lesion.
Apply it
A gelatinous peritoneal specimen initially yields mucin with rare cells. Concentrate additional material and search for epithelial groups, then correlate with operative findings rather than assigning a primary site from the mucin's appearance alone.
Common pitfall: Sparse epithelium can lead to underinterpretation, while assuming an ovarian primary from pelvic location can misdirect classification of a disseminated mucinous process.
15.How does polarized microscopy distinguish common synovial crystals?
Crystal analysis combines shape with optical behavior under compensated polarized light. Monosodium urate crystals are typically needle-shaped and strongly negatively birefringent; calcium pyrophosphate crystals are often rhomboid or rod-shaped and weakly positively birefringent. Intracellular crystals support an inflammatory crystal-associated process, but finding crystals does not independently exclude infection. Preserve appropriate material for microbiologic evaluation when the clinical setting warrants it. The decision depends on crystal identification and the complete inflammatory context rather than cell count or shape alone.
Apply it
A painful swollen joint yields neutrophil-rich fluid containing intracellular needle-shaped, negatively birefringent crystals. Identify urate deposition while preserving material for culture if infection remains clinically plausible, rather than allowing the crystal finding to terminate evaluation.
Common pitfall: Crystal arthritis and infection can coexist. Weak birefringence or suboptimal optics can also make a shape-only classification unreliable without appropriate microscopy and context.
ABPath Cytopathology Content Specifications, January 2026 · JBJI - Guideline for management of septic arthritis in native joints (SANJO)
16.How should a limited CSF specimen be triaged when lymphoma is suspected?
CSF often contains few fragile cells, making prompt processing and intentional allocation essential. Morphology establishes the appearance of the sampled population, while flow cytometry can characterize an abnormal lymphoid population when enough viable cells are available. Neither method should be treated as universally sufficient. Coordinate the requested studies before the specimen is exhausted, and interpret results with treatment history, blood contamination and clinical findings. A paucicellular or degenerated specimen limits the strength of a negative conclusion.
Apply it
A small CSF sample arrives from a patient with suspected leptomeningeal lymphoma. Alert the laboratory promptly, coordinate cytology and appropriate flow allocation, and document cellular limitations rather than placing the entire specimen into a single preparation.
Common pitfall: Delaying processing while awaiting a perfect study plan can destroy diagnostic cells. Conversely, exhausting the sample on flow alone removes the complementary morphologic assessment.
ABPath Cytopathology Content Specifications, January 2026 · CAP-ASCP: Laboratory Workup of Lymphoma in Adults
17.Which findings distinguish a glial tumor from lymphoma in CNS and ocular specimens?
In a CNS squash preparation, cytoplasmic fibrillary processes favor a diffuse glial tumor; discohesive atypical lymphoid cells with lymphoglandular bodies favor lymphoma. Crushing can obscure either pattern, so inspect preserved areas and retain tissue for confirmation. These discriminators were evaluated in an [original intraoperative squash study](https://pubmed.ncbi.nlm.nih.gov/31943445/). In vitreous, an atypical lymphoid population raises vitreoretinal lymphoma rather than a glial lesion. Cell-block CD20 can support B-cell differentiation, while MYD88 L265P testing can add evidence when cytology is scant or equivocal. The mutation result complements cellular assessment; a negative result does not exclude lymphoma. See the [vitreous cell-block study](https://pubmed.ncbi.nlm.nih.gov/26987877/) and [MYD88 diagnostic study](https://pubmed.ncbi.nlm.nih.gov/30027272/).
Apply it
A brain squash contains discohesive atypical cells and lymphoglandular bodies without convincing fibrillary processes. Favor lymphoma over a diffuse glial tumor and confirm the lymphoid phenotype. In a separate vitreous sample with atypical lymphoid cells, use B-cell assessment and appropriate molecular support to investigate vitreoretinal lymphoma.
Common pitfall: Crushed nuclei alone cannot establish lymphoma. CD20 establishes B-cell differentiation rather than malignancy by itself, and absent MYD88 L265P cannot exclude a tumor that lacks the mutation or is poorly represented.
ABPath Cytopathology Content Specifications, January 2026 · CAP-ASCP: Laboratory Workup of Lymphoma in Adults
18.Why is urinary cytology better suited to high-grade disease?
High-grade urothelial carcinoma more often sheds cells with conspicuous nuclear abnormalities, making it a principal target of urinary cytology. Low-grade papillary tumors can shed relatively bland cells that overlap with benign urothelium, reducing sensitivity. A negative result therefore does not exclude a low-grade lesion or replace anatomical evaluation. Interpret the report in relation to the clinical question: evidence against high-grade malignant cells in the sampled material is different from proof that the urinary tract contains no neoplasm.
Apply it
A patient has a papillary bladder lesion on cystoscopy but negative urine cytology. Explain that bland low-grade tumors may be missed cytologically and that the visible lesion still requires its appropriate anatomical and histologic evaluation.
Common pitfall: Treating negative cytology as a universal cancer exclusion test overlooks its grade-dependent performance and can falsely dismiss an anatomically demonstrated urinary tract lesion.
EAU Non-Muscle-Invasive Bladder Cancer Guidelines, March 2026
19.What can a positive urine cytology result localize?
Voided urine samples cells shed along the urinary tract, so malignant urothelial cells can originate from the renal pelvis, ureter, bladder or urethral region. A positive result supports the presence of relevant malignant cells but does not independently identify their anatomical source. Specimen type matters: a selectively obtained upper-tract sample has a different localization context from a voided specimen. Correlate positive cytology with cystoscopy, imaging and appropriately directed sampling instead of assigning a bladder primary by default.
Apply it
Repeated voided specimens contain malignant urothelial cells, but cystoscopy does not show a bladder tumor. Recommend correlation with the remainder of the urinary tract rather than reporting the cytology as proof of an occult bladder primary.
Common pitfall: The commonness of bladder cancer can encourage premature localization. Exfoliated cells in voided urine do not carry a reliable label identifying their site of origin.
EAU Non-Muscle-Invasive Bladder Cancer Guidelines, March 2026
20.How does urine collection affect cytologic interpretation?
Cell preservation depends on collection conditions, dwell time and prompt processing. First-morning urine is undesirable for cytology because prolonged bladder residence can promote degeneration. Instrumented specimens may contain more cohesive urothelial groups and procedure-related changes than voided urine. Knowing whether the specimen is voided, washed or selectively sampled helps avoid misreading expected preparation-related findings. Assess adequacy and atypia in that context, and distinguish a poorly preserved specimen from a truly informative negative result.
Apply it
A first-morning specimen arrives after a long delay and contains extensively degenerated urothelial cells. Explain the preservation limitation and seek a better collected specimen rather than forcing a confident negative or malignant interpretation from damaged nuclei.
Common pitfall: Dark degenerated nuclei can imitate high-grade atypia. The opposite error is to call a poorly preserved sample reassuring simply because no intact malignant cells remain.
EAU Non-Muscle-Invasive Bladder Cancer Guidelines, March 2026
21.Which clues suggest polyomavirus change rather than urothelial carcinoma?
Polyomavirus-associated decoy cells can have enlarged hyperchromatic nuclei and scant cytoplasm, creating overlap with high-grade urothelial carcinoma. Viral nuclear inclusions and the pattern of chromatin alteration provide useful clues, but degeneration can obscure them. Consider immune status, other cells in the specimen and targeted ancillary testing when the distinction remains consequential. Recognizing a viral mimic prevents overcalling carcinoma, while the presence of decoy cells does not exclude a separate malignant population elsewhere in the preparation.
Apply it
A transplant recipient's urine contains cells with enlarged nuclei and dense homogeneous intranuclear material. Evaluate a viral explanation and compare all atypical populations before interpreting the sample as high-grade urothelial carcinoma solely from nuclear darkness.
Common pitfall: Finding a plausible viral mimic should not end the search for independently atypical urothelial cells. Viral infection and neoplasia are not mutually exclusive possibilities.
22.How do TTF-1 and p40 support lung carcinoma subtyping?
In poorly differentiated non-small-cell carcinoma without definite glandular or squamous morphology, TTF-1 and p40 provide a focused subtyping panel. Their staining thresholds differ: focal nuclear TTF-1 positivity can support pulmonary adenocarcinoma in the appropriate clinical context, whereas focal or weak p40 is insufficient for squamous classification. IASLC recommends p40 positivity in more than 50% of tumor nuclei for this interpretation. Confirm that staining involves tumor rather than entrapped benign cells. Integrate morphology and possible metastatic origins, then conserve remaining material for predictive testing.
Apply it
A lung carcinoma has convincing focal nuclear TTF-1 staining and weak p40 staining in 10% of tumor nuclei. With compatible morphology and clinical findings, favor adenocarcinoma; the limited p40 staining does not justify squamous classification or a mixed carcinoma diagnosis.
Common pitfall: Applying the same positivity rule to both markers can misclassify a tumor. Focal TTF-1 can be meaningful, but focal or weak p40 does not meet the recommended squamous interpretation threshold.
IASLC Diagnostic Immunohistochemistry Recommendations, April 2019
23.When is Ki-67 useful in pulmonary neuroendocrine cytology?
Ki-67 can assist when crushed or limited pulmonary neuroendocrine material makes a carcinoid-versus-high-grade neuroendocrine carcinoma distinction difficult. A markedly increased proliferative fraction supports a high-grade process when the morphology fits, while lower proliferation can support a carcinoid interpretation. It is an adjunct rather than a universal lung tumor grading formula. Integrate cell size, nuclear features, necrosis, mitotic activity where assessable and sampling limitations; avoid importing classification thresholds from another organ system without justification.
Apply it
A bronchial biopsy is severely crushed, but preserved cells suggest a neuroendocrine tumor. Assess Ki-67 alongside the intact morphology to help distinguish carcinoid from high-grade neuroendocrine carcinoma, while acknowledging the specimen's limits for complete classification.
Common pitfall: A proliferation stain cannot repair absent morphology or automatically distinguish every neuroendocrine subtype. Organ-specific classification rules should not be transferred indiscriminately between lung and pancreas.
IASLC Diagnostic Immunohistochemistry Recommendations, April 2019
24.Why should molecular testing influence the initial lung specimen plan?
A lung specimen may need to support diagnosis, lineage assignment and treatment-related biomarkers from the same limited tumor population. Planning at collection and initial evaluation helps preserve suitable material rather than discovering after extensive staining that the block is exhausted. Validated cytology preparations can be appropriate ancillary-testing substrates; suitability depends on the specific assay and preparation. Estimate tumor content, coordinate testing and choose a focused diagnostic workup so that obtaining a label does not inadvertently prevent the next clinically necessary decision.
Apply it
A lung FNA confirms carcinoma on direct smears, but the cell block is small. Coordinate diagnostic stains and biomarker allocation before serially cutting the block, considering validated smear-based testing when the laboratory supports that preparation.
Common pitfall: Assuming only a formalin-fixed cell block can support molecular testing may discard useful material. Conversely, an unvalidated preparation should not be used merely because tumor is visible.
25.How does ROSE change decisions during thoracic sampling?
Rapid on-site evaluation provides immediate feedback about whether the sampled material represents the target and whether further passes or different allocation may be useful. It can identify a need for cell-block material, microbiology or hematolymphoid studies before the procedure ends. ROSE is an adequacy and triage process, not a guarantee that every final diagnosis or ancillary assay will succeed. Decisions must still account for procedural safety, target accessibility, tumor distribution and the validated requirements of downstream testing.
Apply it
During EBUS sampling, the first pass yields mostly blood and bronchial cells. Communicate the lack of representative target material and, if procedurally appropriate, request additional sampling with deliberate allocation for the anticipated diagnostic and ancillary studies.
Common pitfall: Calling any cellular smear adequate confuses cellularity with target representation. A preliminary impression also should not be communicated as an unrestricted final diagnosis.
26.Which respiratory cytology findings support Pneumocystis pneumonia?
In bronchoalveolar lavage, Pneumocystis jirovecii can produce foamy alveolar casts containing numerous small cyst forms. Cup-shaped organisms and cyst-wall staining with Grocott methenamine silver support identification; nonspecific foam alone is insufficient. Examine consistent organism morphology within the casts rather than diagnosing infection from isolated foreign particles. An [original BAL cytology series](https://pubmed.ncbi.nlm.nih.gov/36751555/) documents the cast and organism pattern. Studies of [minimal or treated infection](https://pubmed.ncbi.nlm.nih.gov/1709086/) show why absence of conspicuous casts cannot exclude disease. Interpret morphology with immune status and complementary organism testing.
Apply it
An immunocompromised patient with diffuse pulmonary infiltrates has BAL containing foamy casts. Silver staining highlights numerous cup-shaped cyst walls within them. This combination supports Pneumocystis pneumonia rather than interpreting the casts as nonspecific mucus or aspirated food.
Common pitfall: Foamy material without demonstrated organisms is not specific. Conversely, scant or treated infection may lack obvious casts, so their absence is not a reliable exclusion criterion.
27.Which cytologic relationships support hepatocellular differentiation?
Hepatocellular assessment combines polygonal cell morphology with trabecular organization, endothelial relationships and hepatocytic cytoplasmic features. Atypia must be interpreted against benign liver and regenerative change because well-differentiated hepatocellular tumors can overlap cytologically with nonmalignant hepatocytes. Ancillary studies can support hepatocellular lineage, but lineage and malignancy are separate questions. Correlate the aspirate with imaging, background liver disease and histology when needed rather than assuming that a hepatocyte-like population from a liver mass is automatically diagnostic of carcinoma.
Apply it
A liver mass aspirate contains hepatocyte-like cells in thick trabecular groups. Evaluate endothelial relationships, atypia and imaging together, and distinguish evidence for hepatocellular differentiation from the additional evidence required to classify the lesion as malignant.
Common pitfall: A hepatocytic marker identifies differentiation rather than proving malignancy. Benign hepatocytes sampled adjacent to a mass can also create false reassurance about target representation.
28.How can a liver adenocarcinoma be assessed for colorectal origin?
Crowded glandular groups and necrotic debris in a liver aspirate can suggest metastatic colorectal adenocarcinoma, but morphology alone may overlap with other adenocarcinomas, including cholangiocarcinoma. Nuclear SATB2 and CDX2, interpreted with CK20 and comparison to a prior colorectal tumor, can support colorectal origin. CK20 alone is insufficient because other carcinomas can express it. An [original liver needle-biopsy study](https://pubmed.ncbi.nlm.nih.gov/29396302/) supports the combined SATB2/CDX2/CK20 approach. Marker loss can occur in colorectal carcinoma, so a negative panel does not universally exclude that origin.
Apply it
A patient with previous colorectal carcinoma develops multiple liver lesions. The aspirate resembles the prior tumor and shows strong nuclear SATB2 and CDX2 with CK20 expression. The combined findings support metastatic colorectal carcinoma rather than assigning a new cholangiocarcinoma solely because the sample came from liver.
Common pitfall: Neither gland formation nor CK20 positivity independently identifies colorectal origin. Evaluate a coherent phenotype with prior pathology and imaging; an isolated marker should not overrule incompatible findings.
29.Why can a negative biliary brushing fail to exclude malignancy?
Biliary brushings sample cells released from a limited ductal surface. A malignant stricture may shed few diagnostic cells, while inflammation, instrumentation and stenting can produce reactive epithelial atypia. Separate sampling adequacy from the interpretation of the cells actually present. Ancillary methods such as FISH may contribute in selected settings, but their results require integration with cytology and the clinical differential. Persistent radiologic or endoscopic concern should not be dismissed solely because a limited brushing lacks unequivocal malignant cells.
Apply it
A patient has a persistent dominant biliary stricture after stenting. Brushings show inflamed atypical epithelium without definitive carcinoma. Explain the sampling and reactive-change limitations, and correlate with directed ancillary studies and the continuing anatomical concern.
Common pitfall: Reactive atypia can tempt an overcall, while a paucicellular negative brushing can tempt false exclusion. Both errors ignore the specimen's restricted sampling mechanism.
30.What does pancreatic cyst-fluid CEA help classify?
Cyst-fluid CEA can help distinguish mucinous from nonmucinous pancreatic cysts. It does not reliably determine whether a mucinous lesion contains high-grade dysplasia or invasive carcinoma, and it cannot by itself separate IPMN from mucinous cystic neoplasm. Interpret the result with cyst morphology, cytology and ductal anatomy. The transferable principle is to match a biomarker to the question it was evaluated to answer: evidence for mucinous differentiation is different from evidence for malignancy or a specific mucinous subtype.
Apply it
A pancreatic cyst has elevated fluid CEA but bland, scant epithelial cells. Describe the biochemical support for a mucinous cyst while using imaging and other findings, rather than CEA alone, to evaluate subtype and malignant potential.
Common pitfall: Equating an elevated CEA with carcinoma confuses cyst type with grade. A mucinous marker cannot substitute for direct evidence of high-grade or invasive disease.
31.How should pancreatic cyst-fluid amylase be interpreted?
Cyst-fluid amylase reflects pancreatic enzyme exposure. The 2018 European guideline identifies cyst-fluid amylase below 250 U/L as evidence against pseudocyst, reporting 44% sensitivity and 98% specificity for this distinction. The low sensitivity means that many nonpseudocyst lesions will not have amylase below this threshold; a higher result therefore does not establish pseudocyst. Elevated amylase is nonspecific because neoplastic cysts, including intraductal papillary mucinous neoplasms, can communicate with pancreatic ducts. Amylase does not establish mucinous differentiation, epithelial dysplasia grade or malignancy.
Apply it
An aspirated pancreatic cyst has fluid amylase of 180 U/L. This is below 250 U/L and argues against pseudocyst, even if pancreatitis appears in the clinical history. Conversely, a result of 5,000 U/L leaves both pseudocyst and a duct-communicating neoplasm in the differential. Integrate ductal anatomy on imaging, pancreatitis history, cyst-fluid CEA and epithelial cytology to address cyst type and malignant features.
Common pitfall: Do not reverse the exclusion principle: amylase at or above 250 U/L does not diagnose pseudocyst. High amylase neither excludes a mucinous neoplasm nor distinguishes low-grade from high-grade dysplasia or invasive carcinoma.
32.Which findings strengthen a pancreatic adenocarcinoma interpretation?
Pancreatic ductal adenocarcinoma is supported by a coherent constellation of disordered epithelial groups, loss of polarity, nuclear irregularity and other malignant cytologic features. Chronic pancreatitis and procedure-related change can produce atypia, so isolated enlargement or nucleoli are insufficient. Evaluate the degree and distribution of abnormalities across the specimen, including whether an independently malignant population is present. Correlate with the sampled lesion and imaging, and distinguish an atypical but limited sample from one that supports a definitive malignant interpretation.
Apply it
A pancreatic mass aspirate from a patient with chronic pancreatitis contains mostly orderly ducts and one severely disorganized atypical group. Review additional material and the consistency of malignant features before deciding whether a definitive or qualified report is justified.
Common pitfall: Clinical suspicion cannot turn equivocal epithelial atypia into proof of carcinoma. Conversely, a pancreatitis history should not explain away a convincing malignant population.
33.What combination supports Warthin tumor on salivary FNA?
Warthin tumor classically combines oncocytic epithelial sheets with a lymphoid background and cystic or proteinaceous debris. The combination is more useful than any component alone: oncocytes occur in other lesions, and lymphocytes may come from an intraparotid node. Squamous metaplasia, infarction and necrosis can obscure the usual pattern and mimic carcinoma. Search for residual diagnostic oncocytic epithelium and interpret atypia within the full specimen rather than allowing one altered component to dominate the diagnosis.
Apply it
A parotid aspirate contains oncocytic sheets, numerous mature lymphocytes and granular cyst contents. A few squamous cells are present. Evaluate metaplastic Warthin tumor before interpreting the squamous component as evidence of a separate squamous malignancy.
Common pitfall: Necrosis and squamous metaplasia can be alarming but are not independently diagnostic of carcinoma. Equally, oncocytes alone do not establish Warthin tumor without context.
Diagnostic Accuracy and Pitfalls in Fine-Needle Aspiration Interpretation of Warthin Tumor
34.Which cell mixture raises mucoepidermoid carcinoma?
Mucoepidermoid carcinoma may show mucous, intermediate and squamoid cells in a mucinous background. Low-grade cystic lesions can be sparsely cellular and deceptively bland, while oncocytic or metaplastic appearances can overlap with Warthin tumor. Seek the complete epithelial mixture and determine whether apparent mucin represents true extracellular mucin rather than nonspecific cyst debris. The absence of striking nuclear pleomorphism does not exclude a low-grade malignant salivary neoplasm when the overall cell composition is characteristic.
Apply it
A cystic parotid lesion yields mucin, bland mucous cells and small intermediate epithelial cells. Despite limited atypia, assess for mucoepidermoid carcinoma rather than labeling the specimen a simple retention cyst or an oncocytic benign lesion.
Common pitfall: Bland nuclei are compatible with low-grade malignancy. Missing the intermediate-cell component or sampling only cyst fluid can conceal the diagnostically important epithelial population.
Diagnostic Performance of FNA Cytology in Mucoepidermoid Carcinoma
35.When is the Milan SUMP category appropriate?
Salivary gland neoplasm of uncertain malignant potential, or SUMP, applies when the aspirate establishes a neoplasm but its cytologic features cannot reliably determine whether it is benign or malignant. It differs from a benign-neoplasm category, which requires sufficient confidence in benign classification, and from a nondiagnostic specimen, which lacks adequate information for interpretation. Use SUMP to communicate a specific diagnostic boundary rather than as a generic container for every difficult salivary aspirate or every specimen with mild atypia.
Apply it
A cellular salivary aspirate clearly represents a basaloid neoplasm, but overlapping features prevent a confident benign-versus-malignant assignment. Use the uncertainty category that preserves the established neoplastic interpretation rather than calling the specimen nondiagnostic.
Common pitfall: SUMP is not equivalent to insufficient material or proven carcinoma. Its value depends on stating that neoplasia is established while malignant potential remains unresolved.
36.Why cannot thyroid FNA establish follicular carcinoma by cytology alone?
Follicular adenoma and follicular carcinoma can share a microfollicular cytologic pattern. The defining distinction depends on capsular or vascular invasion, which requires examination of the tumor's tissue relationship to its capsule and vessels. An aspirate samples cells and small groups without adequately displaying that interface. Report the appropriate cytologic category rather than claiming a histologic invasion-based diagnosis. Nuclear atypia or cellularity can inform interpretation but cannot replace the architectural evidence required to distinguish these follicular tumors.
Apply it
A thyroid aspirate is highly cellular with crowded microfollicles and little colloid, without diagnostic papillary carcinoma nuclei. Classify the follicular-patterned process appropriately and explain why an aspirate cannot determine capsular or vascular invasion.
Common pitfall: Calling follicular carcinoma from cellularity or microfollicles mistakes a neoplastic pattern for proof of invasion. The relevant distinction is anatomical, not simply the degree of cytologic atypia.
ATA: Thyroid Cytopathology and Histopathology Quality Assurance
37.Which thyroid category names changed in Bethesda 2023?
The 2023 Bethesda thyroid system uses the single names atypia of undetermined significance for category III and follicular neoplasm for category IV. Earlier alternative labels, including follicular lesion of undetermined significance and suspicious for a follicular neoplasm, should be recognized when reviewing historical reports but should not be mistaken for additional current categories. Terminology standardization improves communication; it does not eliminate the need to identify the underlying cytologic pattern or the specimen's limits for histologic classification.
Apply it
A historical report uses the phrase follicular lesion of undetermined significance. When comparing it with a current report, map it to category III terminology rather than interpreting the wording change as a newly introduced disease category.
Common pitfall: Memorizing category numbers without their current names can create apparent disagreements between reports. Terminology changes alone do not prove that a lesion's biological risk changed.
The 2023 Bethesda System for Reporting Thyroid Cytopathology: Original Publication PDF · ABPath Guidelines and Key Manuscripts
38.Why is NIFTP a surgical diagnosis?
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features requires evaluation of an excised lesion to establish the necessary architecture and absence of invasion. FNA may identify a follicular-patterned lesion with relevant nuclear changes, but it cannot adequately examine the entire capsule or exclude an invasive focus. Therefore, a cytology report may raise an appropriate differential without definitively diagnosing NIFTP. The general principle is that a diagnosis defined partly by absence of invasion needs a specimen capable of demonstrating that absence.
Apply it
A thyroid aspirate has a follicular pattern and papillary-like nuclear changes. Explain that NIFTP can enter the differential, but definitive classification requires surgical examination of the lesion rather than a reassuring molecular or cytologic result alone.
Common pitfall: A bland aspirate or favorable ancillary result cannot demonstrate an intact noninvaded capsule. Calling NIFTP definitively before excision overstates what the sampled material establishes.
39.How should suspected medullary thyroid carcinoma be confirmed and contextualized?
Medullary thyroid carcinoma can show plasmacytoid or spindle cells with neuroendocrine chromatin, sometimes accompanied by amyloid. When morphology is suggestive or inconclusive, ancillary evaluation can include calcitonin-related testing and appropriate immunophenotyping rather than relying on appearance alone. The ATA medullary carcinoma guideline also recommends germline RET assessment for patients with apparently sporadic medullary carcinoma. Distinguish confirmation of C-cell tumor differentiation from evaluation of hereditary predisposition: these are separate questions with different implications for the patient and family.
Apply it
A thyroid aspirate contains plasmacytoid cells with granular chromatin and amorphous extracellular material. Pursue calcitonin-supported confirmation and, if medullary carcinoma is established, recognize the separate need to assess possible hereditary disease despite a negative family history.
Common pitfall: Neuroendocrine morphology is not specific to medullary carcinoma. Likewise, an apparently sporadic presentation does not reliably exclude a germline RET-associated syndrome.
40.How can parathyroid tissue be distinguished from a thyroid follicular lesion?
Parathyroid aspirates can mimic thyroid follicular neoplasms. A supporting constellation includes numerous scattered naked nuclei, stippled chromatin and cribriform or three-dimensional epithelial groups; oxyphilic cells may also occur. Colloid-like material or follicle-like groups do not exclude parathyroid origin. PTH measurement in an available needle rinse and appropriately validated PTH and GATA3 immunostaining can support parathyroid differentiation when interpreted with lesion location and serum calcium/PTH. These approaches are described in an [original 81-case cytologic study](https://pubmed.ncbi.nlm.nih.gov/38213192/). Establishing parathyroid origin does not establish carcinoma: cytology cannot reliably resolve the invasion-based distinction between a parathyroid adenoma and carcinoma.
Apply it
A posterior thyroid-region mass yields cribriform groups with stippled nuclei and many naked nuclei. Serum calcium and PTH are elevated, and PTH in an available needle rinse supports parathyroid origin. Interpret the sample as parathyroid tissue rather than a thyroid follicular neoplasm, without assigning malignant behavior from these findings.
Common pitfall: Follicle-like architecture and apparent colloid can anchor interpretation to thyroid. PTH/GATA3 support tissue identity, but neither marker nor the cytologic constellation independently determines malignancy.
41.Why is FNA morphology alone insufficient for many lymphomas?
Lymphoma diagnosis and classification often require integration of cell morphology, immunophenotype, genetic findings and tissue architecture. FNA can provide valuable material for cytology and ancillary studies, but morphology alone may not distinguish reactive conditions from lymphoma or classify the process adequately. Plan sampling around the suspected disease and the information required for treatment. If an aspirate leaves an important architectural or classification question unresolved, obtain an appropriate additional tissue specimen rather than forcing a complete lymphoma label from limited cellular material.
Apply it
A node aspirate shows a monotonous small lymphoid population, but the available studies cannot resolve the classification needed for treatment. Recommend additional appropriate tissue rather than equating a suggestive cytologic pattern with a fully established lymphoma subtype.
Common pitfall: A descriptive lymphoid pattern is not always a complete diagnosis. Conversely, rejecting all FNA material overlooks its useful role when integrated with well-planned ancillary studies.
42.What does lymphoid clonality prove and leave unresolved?
A clonal result identifies a restricted population by the method used, but clonality is not synonymous with clinically significant lymphoma in every setting. Conversely, a negative clonality study does not exclude lymphoma when sampling, assay coverage or the underlying biology limits detection. Interpret molecular or flow findings with morphology, phenotype and clinical context. The correct decision is to determine whether the combined evidence establishes a specific disease, rather than treating a single binary laboratory result as a universal malignancy verdict.
Apply it
A small node sample has a clonal molecular result but reactive-appearing morphology and limited phenotype data. Review the complete evidence and sampling context before issuing a lymphoma diagnosis based solely on the clonality finding.
Common pitfall: Both 'clonal means malignant' and 'polyclonal means benign' are overextensions. Assay results describe sampled populations and require disease-specific interpretation with independent diagnostic evidence.
43.Why does an adult cystic neck mass require more than a benign cyst assumption?
A cystic neck mass can represent a developmental cyst, an inflamed lesion or a cystic metastatic malignancy, including HPV-related squamous carcinoma. Aspirating mostly fluid, macrophages and debris may miss the diagnostically important wall or solid component. Interpret bland or scant material in relation to age, anatomical location and imaging rather than assuming a developmental origin. When malignant squamous cells are identified, targeted ancillary testing and clinical investigation can help connect the nodal process to an appropriate primary-site differential.
Apply it
An adult has a persistent lateral neck cyst with a mural focus on imaging. The aspirate contains mostly macrophages. Describe limited target representation and direct further assessment toward the wall or solid component instead of declaring a branchial cleft cyst.
Common pitfall: Cystic appearance and paucicellularity can create false reassurance. A nonrepresentative aspirate does not resolve the distinction between a developmental cyst and a cystic metastasis.
44.When should breast ER staining be reported as ER-low positive?
For invasive breast carcinoma, ASCO-CAP defines ER-low positive as staining in 1% to 10% of tumor-cell nuclei, with appropriate reporting and attention to controls and assay performance. This special category should not be applied indiscriminately to an unclassified cytology specimen or transferred to DCIS. The guideline recommends ER testing in DCIS to inform potential endocrine benefit, while PgR testing in DCIS is optional. Confirm the disease context before applying a result-specific reporting convention.
Apply it
A validated preparation from established invasive breast carcinoma shows ER staining in 5% of tumor nuclei with adequate controls. Apply the ER-low-positive convention and its reporting context rather than treating the result as either fully negative or strongly positive.
Common pitfall: The percentage alone is insufficient without confirmed invasive disease and reliable testing. The ER-low-positive convention should not automatically be imposed on DCIS or unidentified malignant cells.
45.How can thymoma resemble a lymphoid lesion in mediastinal sampling?
Lymphocyte-rich thymoma contains abundant nonneoplastic thymocytes that can obscure its neoplastic epithelial component. In the original comparative study by Li and colleagues, thymoma-associated thymocytes showed recognizable maturation populations: early surface-CD3-negative cells, immature CD4/CD8 double-positive cells with heterogeneous surface CD3, and mature surface-CD3-positive cells expressing either CD4 or CD8. Their heterogeneous CD3/CD4/CD8 expression often produced a smearing pattern. T-lymphoblastic leukemia/lymphoma instead showed tight populations without this maturation spectrum and frequently showed antigen loss, including loss of CD2, CD5 or surface CD3. These patterns support distinction when integrated with epithelial assessment and imaging.
Apply it
An anterior mediastinal aspirate contains many immature lymphocytes and rare cohesive larger cells. A broad CD4/CD8 double-positive population tapering into single-positive populations, heterogeneous surface CD3 and preserved CD2/CD5/CD7 favor accompanying thymocytes. Demonstrating a cytokeratin-positive epithelial component supports thymoma in the appropriate morphology and imaging context. By comparison, a tight double-positive population with uniform surface-CD3 absence and CD5 loss raises concern for T-lymphoblastic lymphoma. Correlate with the mass distribution and any blood, marrow or nodal involvement.
Common pitfall: Immaturity, TdT expression or CD4/CD8 coexpression alone cannot establish lymphoma because normal thymocytes share these features. A maturation pattern supports thymic tissue but does not by itself distinguish thymoma from thymic hyperplasia; evaluate epithelial morphology and imaging. Sparse epithelial sampling can conceal thymoma.
ABPath Cytopathology Content Specifications, January 2026 · Thymoma%20T-Cell%20Flow.pdf
46.Why can a renal oncocytic aspirate remain indeterminate?
Oncocytic cytoplasm reflects abundant granular cytoplasmic organelles and can occur across more than one renal tumor type. Renal oncocytoma and chromophobe renal cell carcinoma can overlap on limited cytologic material, so a uniform oncocytic appearance does not automatically establish benignity. Evaluate nuclear features, architecture, ancillary findings and imaging while recognizing the sample's limits. A qualified oncocytic-neoplasm interpretation may be more accurate than a definitive benign label when the available material cannot reliably separate the relevant entities.
Apply it
A renal mass aspirate contains uniform granular eosinophilic cells but lacks enough discriminatory architecture or ancillary evidence to resolve oncocytoma versus chromophobe carcinoma. Communicate the oncocytic-neoplasm differential and its limitation instead of guaranteeing a benign oncocytoma.
Common pitfall: Oncocytic is a morphologic description rather than a synonym for benign. A small sample can underrepresent heterogeneous features that matter for renal tumor classification.
Epidemiology Aetiology and Pathology - EAU Guidelines on RCC - Uroweb
47.What must be established before considering biopsy of an indeterminate adrenal mass?
Pheochromocytoma must be excluded before adrenal biopsy is considered because needle manipulation can provoke dangerous catecholamine release. In a patient with extra-adrenal malignancy and an indeterminate adrenal mass, measure plasma free or urinary fractionated metanephrines even when metastasis seems likely. The ESE guideline requires three prerequisites: hormonal inactivity with pheochromocytoma excluded; imaging that has not conclusively established benignity; and an expected biopsy result that would change management. These are prerequisites for considering biopsy, not an instruction to biopsy every eligible lesion. See [ESE recommendations 6.3.1 and 6.3.5](https://academic.oup.com/ejendo/article/189/1/G1/7198474).
Apply it
A patient with lung cancer has an indeterminate adrenal mass whose classification would change staging and treatment. Obtain the biochemical evaluation, including metanephrines, before contemplating biopsy. Only consider sampling after hormonal inactivity is established, imaging remains indeterminate and the anticipated result would alter management.
Common pitfall: A prior cancer diagnosis does not exclude pheochromocytoma. Merely considering a functional lesion, or documenting no characteristic symptoms, is insufficient biochemical exclusion.
48.How can nodular fasciitis be distinguished from a sarcoma on limited sampling?
Nodular fasciitis can grow rapidly and produce a cellular aspirate, yet show plump spindle or myofibroblastic cells with delicate processes, myxoid material and scattered ganglion-like cells. Mitotic activity alone does not establish sarcoma. The cytologic pattern and its diagnostic pitfalls are documented in an [original FNA study](https://pubmed.ncbi.nlm.nih.gov/27525591/). In an appropriate lesion, a USP6 rearrangement supports nodular fasciitis, as assessed in a [molecular differential-diagnosis study](https://pubmed.ncbi.nlm.nih.gov/27271298/). Interpret it with morphology and location because USP6 rearrangements also occur in other lesions. Markedly discordant morphology or behavior requires broader tissue assessment.
Apply it
A small superficial mass enlarging over several weeks yields plump spindle cells, myxoid material and ganglion-like cells without convincing malignant nuclear features. A compatible USP6 rearrangement supports nodular fasciitis rather than diagnosing sarcoma from rapid growth and cellularity.
Common pitfall: Rapid growth, prominent nucleoli and mitoses can create a false malignant impression. Conversely, a generic myxoid spindle-cell pattern or an isolated molecular result should not override incompatible findings.
49.How do age and skeletal location resolve a giant-cell-rich bone differential?
An epiphyseal lesion in an adolescent with an immature skeleton raises chondroblastoma, particularly when giant cells accompany grooved mononuclear cells and chondroid matrix. An epiphyseal or epimetaphyseal lesion reaching the subarticular region in a skeletally mature adult instead favors giant cell tumor when the mononuclear stromal population fits. Nuclear H3K36M staining supports chondroblastoma; nuclear H3G34W staining in mononuclear stromal cells supports giant cell tumor. The osteoclast-type giant cells are not the diagnostic mutant population. An [original FNA/core-biopsy study](https://pubmed.ncbi.nlm.nih.gov/29757500/) evaluated these markers. Negative staining does not universally exclude either tumor.
Apply it
A 15-year-old with open physes has a proximal humeral epiphyseal lesion. The aspirate contains grooved mononuclear cells, chondroid material and giant cells, and the mononuclear cells express H3K36M. The integrated findings support chondroblastoma rather than labeling every giant-cell-rich aspirate giant cell tumor.
Common pitfall: Giant cells alone cannot distinguish these lesions. Interpret mutation-specific staining in the mononuclear cells, and avoid excluding a tumor solely because a particular mutation-specific antibody is negative.
50.How can cytology support prostatic origin in a metastatic adenocarcinoma?
Metastatic prostatic adenocarcinoma may show cohesive or acinar groups with prominent nucleoli, but morphology overlaps with other adenocarcinomas. Nuclear NKX3.1 staining, interpreted with PSA or other appropriate prostatic markers and clinical findings, can support prostatic origin. PSA staining may be focal or absent, so a negative PSA stain alone does not exclude the diagnosis. An [original FNA-smear study](https://pubmed.ncbi.nlm.nih.gov/31175351/) demonstrated the utility of NKX3.1 for conventional and ductal prostatic carcinoma while identifying limited usefulness in prostatic small-cell carcinoma. Urinary exfoliative categories do not substitute for classifying this sampled metastatic tumor.
Apply it
A pelvic-node aspirate from a patient with a prostate mass shows adenocarcinoma with prominent nucleoli. Strong nuclear NKX3.1 and compatible additional findings support metastatic prostatic adenocarcinoma despite weak PSA staining. Confirm consistency with the clinical and prior pathologic findings.
Common pitfall: Do not exclude prostatic origin from negative PSA alone or promise that NKX3.1 detects every prostatic tumor. Small-cell/neuroendocrine transformation requires a different morphologic and ancillary assessment.
ABPath Cytopathology Exam Description · ABPath Cytopathology Examination Blueprint, updated for 2026
51.How does a gastric spindle-cell sample distinguish GIST from a smooth-muscle tumor?
Target the subepithelial mass rather than its normal mucosal covering. In a spindle-cell lesion, DOG1 and KIT/CD117 expression in the lesional cells supports gastrointestinal stromal tumor, whereas diffuse desmin and smooth-muscle actin with absent lesional DOG1/KIT favors smooth-muscle differentiation. SMA alone is insufficient because some GISTs express it. The combined approach is supported by an [original gastrointestinal mesenchymal-tumor study](https://pubmed.ncbi.nlm.nih.gov/20716168/). Interpret the stained cell population carefully: nonneoplastic interstitial cells of Cajal within leiomyomas can express DOG1/KIT, a pitfall documented in an [original study](https://pubmed.ncbi.nlm.nih.gov/24145645/). Smooth-muscle differentiation alone does not distinguish leiomyoma from leiomyosarcoma.
Apply it
A gastric wall mass yields spindle cells with diffuse lesional DOG1 and KIT expression and absent desmin. The integrated findings support GIST. A contrasting sample with diffuse desmin/SMA and only scattered DOG1-positive interstitial cells instead supports a smooth-muscle tumor, whose behavior requires additional assessment.
Common pitfall: Do not diagnose GIST from SMA or scattered KIT/DOG1-positive background cells. A scant aspirate also may not adequately assess mitoses, necrosis or heterogeneity needed for behavior and risk assessment.
Laboratory Management/AdministrationApproximately 15% Written/Practical; 0% Virtual Microscopy.
52.How does fixation determine which cytologic details are preserved?
Preparation and fixation create different but complementary views of a specimen. Air-dried Romanowsky preparations emphasize cytoplasmic and background features, while promptly alcohol-fixed Papanicolaou preparations provide detailed nuclear assessment. Unintended drying of a preparation intended for wet fixation can introduce artifact, and a cell block provides another substrate for morphology and ancillary studies. Plan the preparations before exhausting the sample. A staining preference should not override the need to preserve diagnostically useful features or validated material for subsequent testing.
Apply it
An FNA procedure produces several passes from a small lesion. Allocate material deliberately among air-dried smears, promptly fixed smears and an appropriate ancillary preparation instead of allowing every slide to dry while the diagnostic plan is still being discussed.
Common pitfall: Preparation artifacts can imitate atypia or obscure defining features. Using every pass for one stain can also eliminate complementary morphology and material for necessary ancillary studies.
ABPath Cytopathology Exam Description · ABPath Cytopathology Content Specifications, January 2026
53.What does United States CLIA require for negative gynecologic rescreening?
United States CLIA requires review of at least 10% of gynecologic cases interpreted as negative by individuals qualified to perform the required supervisory review. Selection includes randomly chosen cases and patients or groups with higher-than-average risk of cervical cancer. The review occurs before reporting and is a quality-control process, not a substitute for the initial examination. A laboratory should distinguish this prospective negative-case rescreening from retrospective review triggered by a later significant abnormality, because the purposes and timing differ.
Apply it
A United States laboratory proposes rescreening only easily reviewed negative cases after reports are released. Revise the process to meet the prospective minimum and required selection approach rather than treating any later review as equivalent compliance.
Common pitfall: The minimum percentage is not the entire requirement. Selection method, qualified review and timing matter, and retrospective discrepancy investigation does not replace prospective negative-case rescreening.
54.When does United States CLIA require a five-year cytology look-back?
For current gynecologic cases interpreted as HSIL, adenocarcinoma or another malignant neoplasm, United States CLIA requires review of available normal or negative gynecologic specimens from the preceding five years. The laboratory must document the review and relevant discrepancies and take required reporting action when discrepancies affect patient care. The purpose is to investigate prior sampling or interpretation in light of the current finding. A look-back identifies patterns and opportunities for improvement; it does not automatically prove that every prior negative result was erroneous.
Apply it
A new cervical specimen is interpreted as HSIL. Search for available negative gynecologic material from the preceding five years, review it under the laboratory's process, and document whether a sampling or interpretive discrepancy is identified.
Common pitfall: A later lesion does not make every earlier negative slide a false negative. The review must evaluate the actual prior material rather than infer an error from chronology alone.
55.How should United States CLIA slide workload limits guide staffing?
For manual screening, United States CLIA sets a maximum of 100 slides examined by an individual in a 24-hour period, with that workload performed in no less than eight hours; shorter screening periods require proportional reduction. This is a ceiling rather than a universal productivity target. The laboratory must establish individual workload limits based on performance and applicable requirements. Account for actual screening time and the relevant preparation or device rules rather than equating paid shift length with unrestricted screening capacity.
Apply it
A cytotechnologist has only four hours available for manual screening during an eight-hour shift. The proportional ceiling is 50 slides, subject to any lower individual performance-based limit.
Common pitfall: The regulatory maximum is not a mandatory quota. Administrative time does not become screening time simply because it occurs within the same paid work shift.
56.What numerical criteria guide analyte- and fixation-specific cytology IHC validation?
Different fixation can change antigen detection, so validate each new analyte and corresponding cytology fixation method. CAP recommends 10 positive and 10 negative cytology cases when feasible, documented justification when fewer are available, and consideration of additional cases for predictive markers. Initial validation or verification should achieve at least 90% overall concordance with the comparator or expected results. Assay-specific scoring and intended-use requirements also apply.
Apply it
An alcohol-fixed assay agrees with expected results in 19 of 20 cases comprising 10 positive and 10 negative specimens: 95% overall concordance meets the general threshold. Investigate the discordance and confirm intended-use and scoring requirements before approval. If only eight positive cases are obtainable, document the justification for fewer positives.
Common pitfall: A matching antibody clone does not establish equivalence across fixation methods. Meeting the overall concordance threshold does not waive predictive-marker scoring requirements or justify ignoring a consequential discordance.
57.How does predictive-marker validation differ from a lineage stain check?
A predictive biomarker can direct therapy through a specific scoring method, threshold or clinical indication. Its validation must therefore address the intended assay, specimen preparation and interpretation, rather than merely showing that some expected cells stain. A lineage marker used qualitatively poses a different interpretive task from a predictive result near a treatment threshold. Include appropriate controls and concordance assessment for the intended use, and follow the marker-specific requirements rather than assuming that one generic cytology staining experiment validates all clinical applications.
Apply it
A laboratory obtains attractive staining with a predictive antibody on a new cytology preparation. Before clinical reporting, assess the validated scoring method and intended treatment-related interpretation rather than accepting visual positivity as sufficient evidence of assay performance.
Common pitfall: Technically visible staining does not establish clinically reliable classification. A validation that ignores scoring and intended use can miss errors around a treatment-defining interpretive boundary.
58.How are sensitivity and specificity calculated from diagnostic data?
Sensitivity is true positives divided by all people with the reference-standard condition: TP/(TP+FN). Specificity is true negatives divided by all people without that condition: TN/(TN+FP). The denominators follow disease status, not the index-test result. Define the target condition, reference standard and study population before interpreting either measure. A test can be highly specific yet insufficiently sensitive for exclusion, and biased verification or an unsuitable reference standard can undermine apparently precise performance estimates.
Apply it
A study includes 80 reference-positive cases, of which cytology detects 60, and 120 reference-negative cases, of which 108 test negative. Sensitivity is 60/80 = 75%; specificity is 108/120 = 90%.
Common pitfall: Dividing true positives by all positive test results calculates positive predictive value, not sensitivity. Correct arithmetic cannot repair a poorly defined reference standard or target condition.
59.Why can positive predictive value fall in a lower-prevalence population?
Positive predictive value is TP/(TP+FP): the proportion of positive test results that represent the target condition. Even with unchanged sensitivity and specificity, moving to a lower-prevalence population can reduce PPV because the larger disease-free group generates more false positives relative to true positives. Negative predictive value is TN/(TN+FN) and also depends on the tested population. Performance interpretation therefore requires attention to case mix and clinical setting rather than transplanting a predictive value from a referral cohort into general screening.
Apply it
A biomarker evaluated in a high-risk referral service is introduced into a much lower-risk screening population. Anticipate a lower proportion of true disease among positive results even if the assay's sensitivity and specificity remain unchanged.
Common pitfall: Calling PPV an intrinsic constant of the assay ignores prevalence and case mix. A high referral-center PPV should not automatically be promised to a screening population.
60.How should a cytologic-histologic discrepancy drive quality improvement?
A discrepancy investigation should establish whether the specimens sampled the same lesion, whether either sample was limited, and whether preparation, interpretation or communication contributed. Review identifiers and chronology before attributing the difference to diagnostic error. Document clinically important findings, communicate necessary corrections and use aggregate patterns to improve collection, processing or review practices. Quality improvement depends on identifying a credible mechanism for the discrepancy rather than simply counting disagreements or assuming that the later specimen is an infallible reference.
Apply it
Cytology is malignant while a subsequent small biopsy is benign. Verify specimen identity and target location, review both preparations, and assess sampling before changing either diagnosis. If a reporting error is established, communicate and document the correction promptly.
Common pitfall: Automatically treating histology as correct can hide biopsy sampling error. Automatically defending cytology can hide interpretation error; the investigation must test both possibilities with actual material.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Practise locating diagnostic populations on undotted non-gynecologic and FNA virtual slides; combine low-power architecture with high-power nuclear assessment.
- Prioritize respiratory specimens, effusions, thyroid/parathyroid, pancreaticobiliary and salivary cytology while maintaining coverage of every official outline section.
- Separate tissue lineage, malignancy, anatomical origin and treatment prediction: each requires a different evidentiary question and may require different tests.
- Treat adequacy as purpose-specific: target representation, diagnostic interpretation and ancillary-test suitability are separate decisions.
- Use current reporting-system terminology while recognizing historical labels in prior reports.
- Study United States CLIA rescreening, look-back and workload requirements alongside practical validation and quality-statistics problems.
- Maintain an error log organized by missed discriminating cue, sampling limitation, inappropriate ancillary test or overstatement of certainty.
A practical preparation plan
1. Map the full scope
Work through the January 2026 specifications and mark each section as secure, developing or unfamiliar. Use the 2026 blueprint's separate Written/Practical and Virtual Microscopy percentages to prioritize effort, preserving the unsplit shared genital category.
2. Build paired morphologic comparisons
Review representative slides in contrast: LSIL versus clearing artifact, HSIL versus atrophy, carcinoma versus mesothelial proliferation, reactive ducts versus adenocarcinoma, and benign versus malignant oncocytic differentials. State the decisive cue before reading the diagnosis.
3. Rehearse specimen decisions
For each case, specify what to preserve for smears, cell block, flow, microbiology and molecular studies. Explain which test answers the unresolved question and whether the available preparation is validated.
4. Solve and explain the drills
Complete the 20 questions independently, then justify the correct option and reject each alternative. Use the flashcards for spaced recall of mechanisms, boundaries and calculations rather than answer-position memorization.
5. Add virtual-slide and laboratory practice
Practise systematic slide navigation and timed diagnostic synthesis. Separately calculate diagnostic statistics and apply United States CLIA scenarios.
6. Close selective-guide gaps
Return to every unaddressed official topic, including rarer tumors, infections, procedures, informatics, accreditation and personnel issues. Use supervised cases and the issuer's listed references to extend beyond these 60 concepts.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABPath Cytopathology Exam Description
- ABPath Content Specifications for Examinations
- ABPath Cytopathology Content Specifications, January 2026
- ABPath Guidelines and Key Manuscripts
- IARC Cervical Cytology Atlas: LSIL
- IARC Cervical Cytology Atlas: HSIL
- ASCCP: Unsatisfactory Cytology
- CAP-ASCCP LAST Recommendations
- ATA: Thyroid Cytopathology and Histopathology Quality Assurance
- The 2023 Bethesda System for Reporting Thyroid Cytopathology
- ATA Medullary Thyroid Carcinoma Guidelines, 2015
- Brescia Panel Study: Claudin-4 and BAP1 in Pleural Cytology
- EAU Non-Muscle-Invasive Bladder Cancer Guidelines, March 2026
- IASLC Diagnostic Immunohistochemistry Recommendations, April 2019
- CAP: Collection and Handling of Thoracic Cytology Specimens
- European Pancreatic Cystic Neoplasm Guidelines, 2018
- Original Study of Oncocytoma and Warthin Tumor Aspirates
- Original Mucoepidermoid Carcinoma Cytohistologic Correlation Study
- Milan System, Second Edition: Neoplasm Chapter
- CAP-ASCP: Laboratory Workup of Lymphoma in Adults
- ASCO-CAP Breast ER/PgR Testing Guideline Update, 2020
- 42 CFR 493.1274: Cytology
- CAP IHC Analytic Validation Recommendations, 2024
- FDA Statistical Guidance for Diagnostic-Test Studies
- CDC Clinical Overview of HPV
- ATA: NIFTP
- ABPath Cytopathology Examination Blueprint, updated for 2026
- ABPath Subspecialty Exam Blueprints and Daily Exam Schedules
- The 2023 Bethesda System for Reporting Thyroid Cytopathology: Original Publication PDF
- The Brescia Panel: Original Claudin-4 and BAP1 Study
- Diagnostic Performance of FNA Cytology in Mucoepidermoid Carcinoma
- ABPath Releases Candidate Resource Guide for Exam Preparation
- ABPath Candidate Resource Guide, 2026
- Diagnostic Accuracy and Pitfalls in Fine-Needle Aspiration Interpretation of Warthin Tumor
- ABPath 2026 Cytopathology (CY) Exam Schedule
- Visually recovered ABPath Cytopathology2026 weighted blueprint
- JBJI - Guideline for management of septic arthritis in native joints (SANJO)
- Diagnostic performance of fine needle aspiration cytology in the preoperative identification of mucoepidermoid carcinoma: a cross-sectional diagnostic analytical study
- Epidemiology Aetiology and Pathology - EAU Guidelines on RCC - Uroweb
- CFR-2025-title42-vol5-part493.pdf
- CFR-2022-title42-vol5-part493.pdf
- The cytological diagnosis of <i>Pneumocystis jiroveci</i> pneumonia in bronchoalveolar lavage - CytoJournal
- Thymoma%20T-Cell%20Flow.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.